Why Annexon, Inc.’s (ANNX) Stock Is Up 5.04%
As of Thursday, July 30, Annexon, Inc.’s ANNX share price has surged by 5.04%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Commentary & Analysis
Why Annexon, Inc.’s (ANNX) Stock Is Down 5.23%
As of Thursday, July 16, Annexon, Inc.’s ANNX share price has dipped by 5.23%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Annexon, Inc.’s (ANNX) Stock Is Down 5.22%
As of Friday, July 10, Annexon, Inc.’s ANNX share price has dipped by 5.22%, which has investors questioning if this is right time to buy.Michael Rose
Why Annexon, Inc.’s (ANNX) Stock Is Down 5.60%
As of Wednesday, July 08, Annexon, Inc.’s ANNX share price has dipped by 5.60%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Annexon, Inc.’s (ANNX) Stock Is Up 5.59%
As of Monday, July 06, Annexon, Inc.’s ANNX share price has surged by 5.59%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | ANNX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $982.0 | $286.3 | 45% |
|
| Shares Out (Mil) | 201.0 | 54.2 | 76% |
|
| Institutional Ownership | 98.9% | 92.8% | 83% |
|
| Float (Mil) | 163.8 | 39.7 | 71% |
|
| Beta | 1.22 | 0.94 | 72% |
|
| Avg Daily Volume (000s) | 2,604 | 534 | 85% |
|
| Price Change (52-week) |
136.5% | 58.7% | 94% |
|
| Growth | ANNX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (26.7%) | (10.1%) | 16% |
|
| EPS (5yr) | 20.2% | 16.0% | 69 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (44.0%) | (15.6%) | 9% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 6 | |
| Current EPS | ($0.278) | ($1.050) | ($1.085) | |
| Month Ago EPS | ($0.252) | ($0.982) | ($0.923) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.252) | ($0.982) | ($0.923) | |
| Year/Year Chg | 1.1% | (21.9%) | (79.9%) | |
| Financials | ANNX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($203) | ($43) | 7% |
|
| EPS (TTM) | ($1.127) | ($1.400) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($193) | ($31) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $67 | $2 | 73% |
|
| Long-Term Debt (Q1) (Mil) | $22 | $4 | 33% |
|
| Enterprise Value (Q1) (Mil) | $813 | $160 | 39% |
|
| Valuation | ANNX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.84 | 2.77 | 77% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ANNX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (79.4%) | (47.3%) | 7% |
|
| ROE | (105.3%) | (55.0%) | 9% |
|
| Liabilities to Assets | 24.4% | 29.6% | 17% |
|
| F-Score | 1 | 2 | 1% |
|
Passing Stock Screens
As of 8/20/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Down 5% Screen
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 2.4% |
| +/- S&P 500: | -5.1 |
